Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology
- PMID: 16606908
- DOI: 10.1212/01.wnl.0000206363.57955.1b
Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology
Erratum in
- Neurology. 2006 Jul 25;67(2):299
Abstract
Objective: To define key issues in the management of Parkinson disease (PD) relating to neuroprotective strategies and alternative treatments, and to make evidence-based treatment recommendations.
Methods: Two clinical questions were identified. 1) In a patient diagnosed with PD, are there any therapies that can slow disease progression? 2) Are there any nonstandard pharmacologic or nonpharmacologic therapies that have been shown to improve motor function in PD? Articles were classified according to a four-tiered level of evidence scheme. Recommendations were based on the evidence.
Results and conclusions: 1. Levodopa does not appear to accelerate disease progression. 2. No treatment has been shown to be neuroprotective. 3. There is no evidence that vitamin or food additives can improve motor function in PD. 4. Exercise may be helpful in improving motor function. 5. Speech therapy may be helpful in improving speech volume. 6. No manual therapy has been shown to be helpful in the treatment of motor symptoms, although studies in this area are limited. Further studies using a rigorous scientific method are needed to determine efficacy of alternative therapies.
Comment in
-
Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.Neurology. 2007 Jan 9;68(2):164; author reply 164. doi: 10.1212/01.wnl.0000254819.77545.da. Neurology. 2007. PMID: 17210906 No abstract available.
Similar articles
-
Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.Neurology. 2007 Jan 9;68(2):164; author reply 164. doi: 10.1212/01.wnl.0000254819.77545.da. Neurology. 2007. PMID: 17210906 No abstract available.
-
Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.Neurology. 2006 Apr 11;66(7):968-75. doi: 10.1212/01.wnl.0000215437.80053.d0. Neurology. 2006. PMID: 16606907
-
Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.Neurology. 2006 Apr 11;66(7):996-1002. doi: 10.1212/01.wnl.0000215428.46057.3d. Neurology. 2006. PMID: 16606910
-
Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.Neurology. 2006 Apr 11;66(7):983-95. doi: 10.1212/01.wnl.0000215250.82576.87. Neurology. 2006. PMID: 16606909 Review.
-
Practice parameter: Assessing patients in a neurology practice for risk of falls (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.Neurology. 2008 Feb 5;70(6):473-9. doi: 10.1212/01.wnl.0000299085.18976.20. Neurology. 2008. PMID: 18250292 Review.
Cited by
-
Tango and physiotherapy interventions in Parkinson's disease: a pilot study on efficacy outcomes on motor and cognitive skills.Sci Rep. 2024 May 24;14(1):11855. doi: 10.1038/s41598-024-62786-6. Sci Rep. 2024. PMID: 38789492 Free PMC article.
-
Olfactory status in neurodegeneration with brain iron accumulation disorders.Neurol Sci. 2024 Feb;45(2):647-654. doi: 10.1007/s10072-023-07037-8. Epub 2023 Aug 31. Neurol Sci. 2024. PMID: 37651040
-
Factors affecting the choice of first-line therapy in Parkinson's disease patients in Wales: A population-based study.Saudi Pharm J. 2021 Feb;29(2):206-212. doi: 10.1016/j.jsps.2021.01.004. Epub 2021 Jan 28. Saudi Pharm J. 2021. PMID: 33679182 Free PMC article.
-
Complementary Therapies in Parkinson Disease: a Review of Acupuncture, Tai Chi, Qi Gong, Yoga, and Cannabis.Neurotherapeutics. 2020 Oct;17(4):1434-1455. doi: 10.1007/s13311-020-00900-y. Neurotherapeutics. 2020. PMID: 32785848 Free PMC article. Review.
-
Guidelines on exercise testing and prescription for patients at different stages of Parkinson's disease.Aging Clin Exp Res. 2021 Feb;33(2):221-246. doi: 10.1007/s40520-020-01612-1. Epub 2020 Jun 8. Aging Clin Exp Res. 2021. PMID: 32514871
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical